Journal of Veterinary Clinics (한국임상수의학회지)

The Korean Society of Veterinary Clinics (한국임상수의학회)
권호 표지
DOI QR코드

DOI QR Code

Treatment of Calcinosis Cutis with Minocycline in Five Dogs

  • Cho, Dae-Hee (College of Veterinary Medicine & Research Institute of Veterinary Medicine, Chungnam National University) ;
  • Lee, Wang-Hui (College of Veterinary Medicine & Research Institute of Veterinary Medicine, Chungnam National University) ;
  • Park, Seong-Jun (College of Veterinary Medicine & Research Institute of Veterinary Medicine, Chungnam National University)
  • Received : 2017.03.28
  • Accepted : 2017.04.10
  • Published : 2017.04.28
Download PDF
⟨ Previous Next ⟩

Abstract

Calcinosis cutis is a chronic condition characterized by insoluble calcified deposits in the skin and subcutaneous tissue. Although there is no uniformly effective treatment for calcinosis cutis, minocycline therapy has demonstrated varying degrees of benefit in humans. Five client-owned dogs with calcinosis cutis were included. Minocycline was administered orally in a dose of 10 mg/kg bodyweight twice a day. Treatment was repeated every day until complete remission. The efficacy of minocycline was evaluated within this period. The side effects of minocycline were monitored and reported by the owners and veterinarians. Of the 5 dogs with calcinosis cutis, which was classified as the dystrophic form, four dogs had a complete remission of calcinosis cutis and one dog had a partial response. The major improvement was a reduction in the size of the calcified deposits and reduction in inflammation associated with them. The duration of remission was $9.1{\pm}2.2$ weeks. The adverse effects, observed in one dog, were anorexia and vomiting. Minocycline may be effective in the control of calcinosis cutis in dogs.

Keywords

References

  1. Ahrens FA, Martin RJ. Antimicrobial drugs. In: Hsu WH ed. Handbook of veterinary pharmacology. Iowa: Wiley-Blackwell. 2008; 357-385.
  2. Beale KM, Morris DO. Treatment of canine calcinosis cutis with dimethylsulfoxide gel. Proc Annu Memb Meet Am Acad Vet Dermatol /Am Coll Vet Dermatol 1998; 14: 97.
  3. Cho NY, Cho DH, Choi HJ, Jeong SM, Lee YW, Park SJ. Clinical trial of diltiazem on dystrophic calcinosis cutis in a dog. Korean J Vet Res 2013; 53:181-184. https://doi.org/10.14405/kjvr.2013.53.3.181
  4. Cohen H, Solomon V, Alferiev IS, Bruer E, Ornoy A, Patlas N, Eidelman N, Hagele G, Golomb G. Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders. Phar Res 1998; 15: 606-613. https://doi.org/10.1023/A:1011990129437
  5. Doerr KA, Outerbridge CA, White SD, Kass PH, Shiraki R, Lam AT, Affolter VK. Calcinosis cutis in dogs: histopathological and clinical analysis of 46 cases. Vet Dermatol 2013; 24: 355-361. https://doi.org/10.1111/vde.12026
  6. Frazier KS, Hullinger GA, Liggett AD, Hines ME 2nd. Multiple cutaneous metaplastic ossification associated with iatrogenic hyperglucocorticoidism. J Vet Diagn Invest 1998; 10: 303-307. https://doi.org/10.1177/104063879801000318
  7. Gross TL, Ihrke PJ, Walder EJ. Degenerative, dysplastic and depositional diseases of dermal connective tissue. In: Skin diseases of the dog and cat: clinical and histopathologic diagnosis, 2nd ed. Oxford: Blackwell Science Ltd. 2005: 373-377.
  8. Hsu K, Snead E, Davies J, Carr A. Iatrogenic hyperadrenocorticism, calcinosis cutis, and myocardial infarction in a dog treated for IMT. J Am Anim Hosp Assoc 2012; 48: 209-215. https://doi.org/10.5326/JAAHA-MS-5740
  9. Huang HP, Yang HL, Liang SL, Lien YH, Chen KY. Iatrogenic hyperadrenocorticism in 28 dogs. J Am Anim Hosp Assoc 1999; 35: 200-207. https://doi.org/10.5326/15473317-35-3-200
  10. Miller Jr. WH, Griffin CE, Campbell KL. Neoplastic and non-Neoplastic Tumors. In: Muller and Kirk's small animal dermatology, 7th ed. St. Louis: Elsevier. 2013: 831-832.
  11. Muller A, Degorce-Rubiales F, Guaguere E. Metastatic calcinosis (including calcinosis cutis) in a young dog with multiple urinary tract abnormalities. Vet Dermatol 2011; 22: 279-283. https://doi.org/10.1111/j.1365-3164.2010.00919.x
  12. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-21494. https://doi.org/10.1074/jbc.274.31.21491
  13. Perret L, Tait CP. Non-antibiotic properties of tetracyclines and their clinical application in dermatology. Australas J Dermatol 2014; 55: 111-118. https://doi.org/10.1111/ajd.12075
  14. Plumb DC. Minocycline HCl. In: Plumb's veterinary drug handbook, 7th ed. Iowa: Wiley-Blackwell. 2011: 937-939.
  15. Reiter N, El-Shabrawi L, Leinweber B, Berghold A, Aberer E. Calcinosis cutis: part II. Treatment options. J Am Acad Dermatol 2011; 65: 15-22. https://doi.org/10.1016/j.jaad.2010.08.039
  16. Robertson LP, Marshall RW, Hickling P. Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline. Ann Rheum Dis 2003; 62: 267-269. https://doi.org/10.1136/ard.62.3.267
  17. Santavirta S, Takagi M, Konttinen YT. Inhibitory effect of cephalothin on matrix metalloproteinase activity around loose hip prostheses. Antimicrob Agents Chemother 1996; 40: 244-246.
  18. Sapadin AN, Fleischmajer R. Tetracycline: Nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006; 54: 258-265. https://doi.org/10.1016/j.jaad.2005.10.004
  19. Tebb AJ, Arteaga A, Evans H, Ramsey IK. Canine hyperadrenocorticism: effects of trilostane on parathyroid hormone, calcium and phosphate concentrations. J Small Anim Pract 2005; 46: 537-542. https://doi.org/10.1111/j.1748-5827.2005.tb00283.x
  20. Touart DM, Sau P. Cutaneous deposition diseases. Part II. J Am Acad Dermatol 1998; 39: 527-544. https://doi.org/10.1016/S0190-9622(98)70001-5
  21. Zur G, White SD. Hyperadrenocorticism in 10 dogs with skin lesions as the only presenting clinical signs. J Am Anim Hosp Assoc 2011; 47: 419-427. https://doi.org/10.5326/JAAHA-MS-5623